Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome

Kidney International

Volumn 66, Issue 1, 2004, Pages 262-267

  Vaziri, Nosratola D ^a,b   Kim, Choong H ^a   Phan, Dennis ^a   Kim, Sara ^a   Liang, Kaihui ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DGAT; Hyperlipidemia; Liver; Nephrotic syndrome; Proteinuria; Renal disease; Triglyceride synthesis

Indexed keywords

ACYL COENZYME A; DIACYLGLYCEROL ACYLTRANSFERASE; FATTY ACID; ISOENZYME; LIVER ENZYME; MESSENGER RNA; PLACEBO; PUROMYCIN AMINONUCLEOSIDE; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; INJECTION; MALE; MICROSOME; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; STATISTICAL SIGNIFICANCE; UPREGULATION;

EID: 3042845638     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00724.x     Document Type: Article

References (41)

1. VAZIRI ND: Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63:1964-1976, 2003
2. JOVEN J, VILLABONA C, VILELLA E, et al: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579-584, 1990
3. WHEELER DC, BERNARD DB: Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment. Am J Kidney Dis 23:331-346, 1994
4. APPEL G: Lipid abnormalities in renal disease. Kidney Int 39:169-183, 1991
5. RADHAKRISHNAN J, APPEL AS, VALERI A, APPEL GB: The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 22:135-142, 1993
6. DE SAIN-VAN DER VELDEN MG, KAYSEN GA, BARRETT HA: Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53:994-1001, 1998
7. GARBER DW, GOTTLIEB BA, MARSH JB, SPARKS CE: Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 74:1375-1383, 1984
8. WARWICK GL, PACKARD CJ, DEMANT T, et al: Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 40:129-138, 1991
9. KAYSEN GA, MEHENDRU L, PAN XM, STAPRANS I: Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis. Am J Physiol 263:F335-F341, 1992
10. DAVIES RW, STAPRANS I, HUTCHISON FN, KAYSEN GA: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 86:600-605, 1990
11. SHEARER GC, STEVENSON FT, ATKINSON DN, et al: Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 59:179-189, 2001
12. LIANG K, VAZIRI ND: Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 130:387-394, 1997
13. SATO T, LIANG K, VAZIRI ND: Downregulation of lipoprotein lipase and VLDL receptor in rats with food glomerulosclerosis. Kidney Int 61:157-162, 2002
14. LIANG K, VAZIRI ND: Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 51:1933-1937, 1997
15. LIANG K, VAZIRI ND: Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 51:1761-1765, 1997
16. JOLES JA, BIJLEVELD C, VAN TOL A, et al: Plasma triglyceride levels are higher in nephrotic than in analbuminemic rats despite a similar increase in hepatic triglyceride secretion. Kidney Int 47:566-572, 1995
17. JOLES J A, BIJLEVELD C, VAN TOL A, et al: Estrogen replacement during hypoalbuminemia may enhance atherosclerotic risk. J Am Soc Nephrol 12:1870-1876, 1997
18. SHAFRIR E, BRENNER T: Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis. I: Studies in rat in vivo. Lipids 14:695-702, 1979
19. GHERARDI E, CALANDRA S: Experimental nephrotic syndrome induced in the rat by puromycin aminonucleoside: Hepatic synthesis of neutral lipids and phospholipids from 3H-water and 3H-palmitate. Lipids 15:108-112, 1980
20. FARESE RV, JR., CASES S, SMITH SJ: Triglyceride synthesis: Insights from the cloning of diacylglycerol acyltransferase. Curr Opin Lipidol 11:229-234, 2000
21. WEISS SB, KENNEDY EP, KIYASU JY: The enzymatic synthesis of triglycerides. J Biol Chem 235:40-44, 1960
22. POLOKOFF MA, BELL RM: Solubilization, partial purification and characterization of rat liver microsomal diacylglycerol acyltransferase. Biochim Biophys Acta 818:129-142, 1980
23. ANDERSSON M, WETTESTEN M, BOREN J, et al: Purification of diacylglycerol: Acyltransferase from rat liver to near homogeneity. J Lipid Res 35:535-545, 1994
24. CASES S, SMITH SJ, ZHENG YW, et al: Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A 95:13018-13023, 1998
25. BUHMAN KK, SMITH SJ, STONE SJ, et al: DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 277:25474-25479, 2002
26. SMITH SJ, CASES S, JENSEN DR, et al: Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. Nat Genet 25:87-90, 2000
27. CASES S, STONE SJ, ZHOU P, et al: Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 276:38870-38876, 2001
28. LIANG K, VAZIRI ND: HMG-CoA reductase, cholesterol 7a-hydroxylase, LCAT, ACAT, LDL receptor and SRB-1 in hereditary analbuminemia. Kidney Int 64:192-198, 2003
29. LIANG K, VAZIRI ND: Upregulation of Acyl-CoA: Cholesterol acyl-transferase (ACAT) in chronic renal failure. Am J Physiol Endocrine Metab 283:E676-E681, 2001
30. COLEMAN RA: Diacylglycerol acyltransferase and monoacylglycerol acyltransferase from liver and intestine. Methods in Enzymology 209:98-101, 1992
31. MULLER PY, JANOVJAK H, MISEREZ AR, DOBBIE Z: Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32:1372-1379, 2002
32. VAZIRI ND, LIANG KH: Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48:1979-1985, 1995
33. VAZIRI ND, SATO T, LIANG K, et al: Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int 63:1756-1763, 2003
34. LIANG KH, OVEISI F, VAZIRI ND: Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin induced nephrosis. Kidney Int 49:855-860, 1996
35. VAZIRI ND, LIANG K: Downregulation of hepatic LDL, receptor expression in experimental nephrosis. Kidney Int 50:887-893, 1996
36. VAZIRI ND, LIANG K, PARK JS: Acquired lecithin: Cholesterol acyl-transferase (LCAT) deficiency in nephrotic syndrome. Am J Phsyiol 49:F823-F829, 2001
37. LIANG K, VAZIRI ND: Downregulation of hepatic high-density lipoprotein receptor, SR-B1 in nephrotic syndrome. Kidney Int 56:621-626, 1999
38. VAZIRI ND, LIANG KH: Upregulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 61:1769-1775, 2002
39. HAAGSMAN HP, DE HAAS CG, GEELEN MJ, VAN GOLDE LM: Regulation of triacylglycerol synthesis in the liver. Modulation of diacylglycerol acyltransferase activity in vitro. J Biol Chem 257:10593-10598, 1982
40. HAAGSMAN HP, VAN GOLDE LM: Synthesis and secretion of very low density lipoproteins by isolated rat hepatocytes in suspension: Role of diacylglycerol acyltransferase. Arch Biochem Biophys 208:395-402, 1981
41. SUNDLER R, AKESSON B, NILSSON A: Effect of different fatty acids on glycerolipid synthesis in isolated rat hepatocytes. J Biol Chem 249:5102-5107, 1974